NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Charm Therapeutics

Charm Therapeutics

Private
LondonHealthcare & Life Scienceshttps://charmtx.com/

Last Round

Series B

Sep 2, 2025

Total Funding Raised

$130M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Charm Therapeutics is a biotechnology company that utilizes a proprietary AI-driven drug discovery platform, DragonFold, to develop transformative medicines for patients with challenging diseases such as cancer.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoverysmall molecule therapeuticsprotein-ligand co-foldingAI drug discoveryDragonFoldundruggable proteinsin silico drug designdeep learningbiotechcomputational biologyoncologypharma collaborationprotein structure predictionAI-native biotechmenin inhibitors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Charm Therapeutics Comparables

Compare Charm Therapeutics with similar companies based on industry and business-model similarity.

Charm Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Genesis Molecular AI
83%
Boltz
81%
Iambic Therapeutics
81%

Charm Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 2, 2025
VC RoundApr 14, 2023
Series AJun 9, 2022

Key People

Founding team and executive leadership

Laksh Aithani

Founder, CEO And Board Member

Founding Team

Laura Hare

Chief Operating Officer

Executive Team

Charm Therapeutics Investors

Notable investors and investment history

Charm Therapeutics investors
InvestorRounds
Braavos Investment AdvisersSeries A
New Enterprise Associates (NEA)Series B
Khosla VenturesSeries A, Series B
Grep VCSeries A
F-Prime CapitalSeries B, Series A
OrbiMedSeries B, Series A
Venture HighwaySeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 8, 2025

    Dr. Erkut Bahceci appointed as the new Chief Medical Officer.

  • Sep 2, 2025

    $80M round completed.

Charm Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Charm Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Charm Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range32
Year Founded2021
Last FundingSep 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.